Background
Methods
Statistical analysis
Results
General characteristics of the whole population
ET | PV | Total | |
---|---|---|---|
N, (%) | 305 (64) | 172 (36) | 477 |
Sex (M/F), n (%) | 112/193 (37/63) | 91/81 (53/47) | 203/274 (43/57) |
Age, years, median (5th–95th percentiles) | 58.0 (27.7–83.0) | 58.3 (35.5–82.0) | 58.0 (28.3–82.7) |
Mutational status, n (%) | |||
Triple negatives | 57 (18) | 9 (5) | 66 (14) |
CALR | 44 (14) | 0 (0) | 44 (9) |
MPLW515L/K | 14 (5) | 0 (0) | 14 (3) |
JAK2V617F hetero | 176 (58) | 95 (55) | 271 (57) |
JAK2V617F homo | 14 (5) | 64 (37) | 78 (16) |
JAK2 exon 12 mutation | 0 (0) | 4 (2) | 4 (1) |
Hs-CRP, mg/L, median (5th–95th percentiles) | 0.83 (0.03–7.96) | 0.87 (0.03–6.43) | 0.83 (0.03–7.53) |
PTX3, ng/mL, median (5th–95th percentiles) | 4.55 (0.58–14.95) | 5.88 (0.42–22.96) | 4.83 (0.54–18.48) |
Driver mutations and PTX3 and hs-CRP values distribution
Clinical outcomes according to mutational status and hs-CRP and PTX3 values
Hs-CRP ≥0.8 mg/La
| PTX-3 ≥4.8 ng/mLa
| |||||
---|---|---|---|---|---|---|
OR | 95% CI |
p
| OR | 95% CI |
p
| |
Thrombosis (n = 55) | ||||||
Unadjusted |
2.57
|
1.39–4.75
|
0.003
| 0.66 | 0.37–1.16 | 0.145 |
Adjusted for | ||||||
+ Male sex |
2.57
|
1.39–4.75
|
0.003
| 0.66 | 0.37–1.16 | 0.146 |
+ Age at diagnosis |
2.56
|
1.38–4.73
|
0.003
| 0.65 | 0.37–1.15 | 0.139 |
+ PV disease |
2.59
|
1.40–4.81
|
0.003
| 0.60 | 0.34–1.07 | 0.085 |
+ Cytoreduction + antiplatelet agents |
2.60
|
1.37–4.95
|
0.003
| 0.57 | 0.31–1.04 | 0.068 |
+ JAK2V617F homo |
2.60
|
1.37–4.95
|
0.003
| 0.57 | 0.31–1.04 | 0.066 |
Bleeding (n = 43) | ||||||
Unadjusted | 0.77 | 0.41–1.45 | 0.419 | 1.07 | 0.57–2.02 | 0.831 |
Adjusted for | ||||||
+ Male sex | 0.77 | 0.41–1.46 | 0.428 | 1.07 | 0.57–2.01 | 0.842 |
+ Age at diagnosis | 0.84 | 0.44–1.61 | 0.596 | 1.06 | 0.56–2.01 | 0.864 |
+ PV disease | 0.84 | 0.44–1.62 | 0.603 | 0.97 | 0.50–1.86 | 0.920 |
+ Cytoreduction+ antiplatelet agents | 0.82 | 0.43–1.59 | 0.557 | 0.95 | 0.49–1.84 | 0.883 |
+ JAK2V617F homo | 0.83 | 0.43–1.60 | 0.574 | 0.92 | 0.48–1.79 | 0.815 |
Haematological evolution (n = 33) | ||||||
Unadjusted |
2.70
|
1.23–5.95
|
0.013
|
1.84
|
1.02–3.96
|
0.044
|
Adjusted for | ||||||
+ Male sex |
2.66
|
1.20–5.86
|
0.015
|
1.87
|
1.02–3.99
|
0.042
|
+ Age at diagnosis |
2.61
|
1.18–2.88
|
0.018
|
1.84
|
1.01–3.98
|
0.046
|
+ PV disease |
2.70
|
1.21–6.01
|
0.015
| 1.59 | 0.72–3.48 | 0.251 |
+ Cytoreduction + antiplatelet agents |
2.72
|
1.21–6.15
|
0.016
| 1.64 | 0.74–3.63 | 0.225 |
+ JAK2V617F homo |
2.79
|
1.23–6.32
|
0.014
| 1.55 | 0.69–3.46 | 0.286 |
Death (n = 56) | ||||||
Unadjusted |
3.93
|
2.01–7.68
|
<.0001
|
1.58
|
1.10–2.84
|
0.039
|
Adjusted for | ||||||
+ Male sex |
3.86
|
1.98–7.55
|
<.0001
|
1.61
|
1.09–2.85
|
0.041
|
+ Age at diagnosis |
4.45
|
2.16–9.15
|
<.0001
|
1.56
|
1.05–2.44
|
0.042
|
+ PV disease |
4.65
|
2.24–9.65
|
<.0001
| 1.14 | 0.60–2.17 | 0.680 |
+ Cytoreduction + antiplatelet agents |
5.26
|
2.47–11.2
|
<.0001
| 1.16 | 0.60–2.22 | 0.662 |
+ JAK2V617F homo |
5.41
|
2.53–11.6
|
<.0001
| 1.11 | 0.58–2.15 | 0.750 |